Edwards Lifesciences (EW) VP has 109 shares withheld for taxes after vesting

Rhea-AI Filing Summary

Edwards Lifesciences Corp corporate vice president Annette Bruls reported a routine tax-related share disposition. On 2026-07-11, 109 shares of common stock were withheld at $92.21 per share to satisfy tax withholding obligations tied to vesting under Rule 16b-3(e). Following this withholding, she holds 20,628 shares of Edwards Lifesciences common stock directly.

Insider Trade Summary

Net Seller: 109 shares

Net Sell 1 txn

Insider Bruls Annette

Role CVP, EMEACLA

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	109	$92.21	$10K

Holdings After Transaction: Common Stock — 20,628 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e).

Key Figures

Shares withheld for taxes: 109 shares Withholding price: $92.21 per share Shares held after transaction: 20,628 shares

3 metrics

Shares withheld for taxes 109 shares Shares of common stock withheld to satisfy tax obligations on 2026-07-11

Withholding price $92.21 per share Value used for tax-withholding disposition of 109 shares

Shares held after transaction 20,628 shares Direct holdings of common stock following the tax-withholding transaction

Key Terms

tax withholding obligations, Rule 16b-3(e), Common Stock

3 terms

tax withholding obligations financial

"shares withheld by the Issuer to satisfy tax withholding obligations incident"

Rule 16b-3(e) regulatory

"obligations incident to the vesting of securities in accordance with Rule 16b-3(e)"

Common Stock financial

"security_title: Common Stock, transaction of 109.0000 shares"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/13/2026 - 04:09 PM Accepted by SEC EDGAR 07/13/2026 - 04:09 PM Learn about SEC filing dates

FAQ

What insider transaction did Edwards Lifesciences (EW) report for Annette Bruls?

Annette Bruls reported a tax-related share withholding of 109 shares of Edwards Lifesciences common stock on 2026-07-11, linked to the vesting of equity awards.

How many Edwards Lifesciences (EW) shares were withheld for taxes in this Form 4?

The filing shows 109 shares of Edwards Lifesciences common stock were withheld at $92.21 per share to cover tax withholding obligations tied to vesting.

Does the Edwards Lifesciences (EW) Form 4 reflect an open-market sale by Annette Bruls?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. Shares were withheld by the issuer to satisfy tax obligations on vesting securities.

How many Edwards Lifesciences (EW) shares does Annette Bruls hold after the reported transaction?

After the tax-withholding transaction, Annette Bruls directly holds 20,628 shares of Edwards Lifesciences common stock, as disclosed in the Form 4 filing.

What SEC rule is cited in the Edwards Lifesciences (EW) Form 4 footnote?

The footnote cites Rule 16b-3(e), explaining that the shares were withheld by Edwards Lifesciences to cover tax withholding obligations upon vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bruls Annette

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, EMEACLA

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/11/2026		F(1)		109	D	$92.21	20,628	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e).

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)